Transgene is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.

Employees

145

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
02/07/26	EUR 0.7270	-0.27%	3,647
01/07/26	EUR 0.7290	+0.55%	16,612
30/06/26	EUR 0.7250	-1.49%	46,461
29/06/26	EUR 0.7360	+0.68%	33,195
26/06/26	EUR 0.7310	0.00%	28,692

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7290EUR

Average target price

1.100EUR

Spread / Average Target

+50.89%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Real-time Euronext Paris Other stock markets 05:01:23 02/07/26 pm AEST			5-day change	1st Jan Change
0.7270 ^EUR	-0.27%		-0.55%	-24.27%

30/06	Transgene SA - Special Call
25/06	Oddo BHF Stays Positive on Transgene

Market Cap	200M 227M 184M 171M 323M 21.62B 330M 2.21B 856M 10.61B 854M 835M 36.93B	P/E 2026 *	-5.21x	P/E 2027 *	-3.31x
Enterprise Value	130M 149M 120M 112M 211M 14.13B 215M 1.44B 560M 6.93B 558M 546M 24.13B	EV / Sales 2026 *	18.1x	EV / Sales 2027 *	26.7x
Free-Float	19.4%	Yield 2026 *	-	Yield 2027 *	-

30/06	Transgene SA - Special Call
25/06	Oddo BHF Stays Positive on Transgene
25/06	Positive Preclinical Data for a Transgene Vaccine
25/06	Transgene Presents Preclinical Data Demonstrating Robust Protection Against Mpox With Its Novel Scalable Cell Line?Derived MVA Vaccine Candidate TG-MVATM	CI
22/06	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	CI
22/06	Transgene launches a clinical trial evaluating TG4070 with nivolumab
22/06	Transgene Begins Phase 1 Trial of Non-small Cell Lung Cancer Vaccine	MT
23/05	Transgene SA Announces Board Appointments	CI
13/04	Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer	CI
07/04	Transgene stands out following licensing agreement with NEC Bio
03/04	Transgene, NEC Bio Enter Partnership to Develop Cancer Vaccine	MT
03/04	Transgene and NEC Bio Sign License Agreement for TG4050 Development in Head and Neck Cancer	CI
03/04	Transgene & NEC Bio sign license agreement to prepare next steps of development of TG4050 in head & neck cancer	RE

25/06	Oddo BHF Stays Positive on Transgene
07/04	Transgene stands out following licensing agreement with NEC Bio
28/11	Oddo BHF Lowers Target Price on Transgene but Remains Upbeat
13/10/25	Transgene and BioInvent International AB Jointly Present a Poster on Transational Data and Updated Clinical Results from the Phase I Study of BT-001	CI
19/09/25	Transgene: analysts reiterate their recommendations after results

Transgene Stock

Stocks

TNG

FR0005175080

Biotechnology & Medical Research

Valuation: Transgene

Chart: Transgene

Latest news : Transgene

Last Transcript: Transgene

Analysts' recommendations: Transgene

Press Releases: Transgene

News in other languages: Transgene

Quotes and Performance

Course Extremes

Managers and Directors: Transgene

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

25/06	Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026	GL
22/06	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	GL
26/05	Transgene : Investor presentation (20260526 Transgene Investor Presentation)	PU
26/05	Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases	GL
23/05	Transgene’s Combined General Meeting of May 22, 2026	GL

25/06	Oddo BHF toujours positif sur Transgene
25/06	Des données précliniques positives pour un vaccin de Transgene
25/06	Bourse : Micron on fire, Volkswagen lâche du lest, Renault réduit la voilure
25/06	Micron, et ça repart
25/06	Transgene présente des données précliniques de son vaccin innovant contre le mpox produit sur lignée cellulaire, TG-MVA

1 day	-0.27%
1 week	-0.55%
Current month	+0.28%
1 month	-9.69%
3 months	-1.76%
6 months	-23.63%
Current year	-24.27%

1 week	0.72	0.74
1 month	0.72	0.81
Current year	0.72	1.03
1 year	0.72	1.5
3 years	0.53	1.86
5 years	0.53	2.99
10 years	0.53	3.79

Manager	Title	Age	Since
Alessandro Riva CEO	Chief Executive Officer	65	01/06/2023
Lucie Larguier DFI	Director of Finance/CFO	-	27/03/2024
Simone Steiner CTO	Chief Tech/Sci/R&D Officer	-	02/04/2025

Director	Title	Age	Since
Benoît Habert BRD	Director/Board Member	61	27/07/2010
Jean-Luc Bélingard BRD	Director/Board Member	76	19/06/2013
Alain Mérieux BRD	Director/Board Member	88	01/01/2007

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/12	Compagnie Merieux Alliance SAS	Buy	Company	84,745,400	63.8367%
02/12	Compagnie Merieux Alliance SAS	Buy	Company	38,492,172	28.9953%
02/08/24	Compagnie Merieux Alliance SAS	Buy	Company	30,898,876	23.3562%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRANSGENE	-0.27%	-0.55%	-7.51%	-60.05%	227M
ARGENX SE	+1.61%	+3.20%	+72.47%	+130.91%	56.21B
WUXI APPTEC CO., LTD.	+0.55%	+8.49%	+77.09%	+100.93%	55.38B
BIONTECH SE	+0.93%	+4.11%	-12.64%	-12.98%	23.75B
INSMED INCORPORATED	+0.36%	+3.42%	+9.61%	+407.11%	23.19B
WUXI BIOLOGICS (CAYMAN) INC.	+3.18%	+7.73%	+39.03%	-6.40%	18.14B
GENMAB A/S	+1.25%	+5.51%	+36.93%	-30.23%	16.84B
PHARMAESSENTIA CORPORATION	+1.49%	+17.24%	+174.91%	+344.55%	15.86B
EXELIXIS, INC.	-0.83%	+2.06%	+23.70%	+182.37%	13.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+7.11%	+13.04%	+41.76%	-	12.97B
Average	+1.51%	+6.16%	+45.53%	+117.35%	23.61B
Weighted average by Cap.	+1.41%	+6.60%	+56.03%	+131.65%

	2026 *	2027 *
Net sales	7.2M 8.2M 6.63M 6.18M 11.65M 780M 11.88M 79.71M 30.88M 383M 30.79M 30.12M 1.33B	7.2M 8.2M 6.63M 6.18M 11.65M 780M 11.88M 79.71M 30.88M 383M 30.79M 30.12M 1.33B
Net income	-38.2M -43.51M -35.16M -32.76M -61.79M -4.14B -63.05M -423M -164M -2.03B -163M -160M -7.07B	-61.6M -70.16M -56.7M -52.83M -99.64M -6.67B -102M -682M -264M -3.27B -263M -258M -11.39B
Net Debt	-69.2M -78.82M -63.7M -59.35M -112M -7.49B -114M -766M -297M -3.68B -296M -290M -12.8B	-7.7M -8.77M -7.09M -6.6M -12.46M -834M -12.71M -85.25M -33.03M -409M -32.93M -32.22M -1.42B